Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Ras pathway activation is linked to malignant and metastatic cancer, poor patient prognosis, and reduced effectiveness of radiotherapy.
• Ras activation increases cancer cell survival and tumor growth delay resistance after irradiation.
• Clinical radiotherapy outcomes are negatively impacted by Ras pathway activation, leading to local failure and decreased survival.

Purpose of the Study:

• To investigate the potential of inhibiting Ras activation as a strategy for radiosensitization in cancer therapy.
• To evaluate the role of prenyltransferase inhibitors in enhancing cancer cell radiosensitivity.

Main Methods:

• Preclinical studies assessing Ras activation effects on cancer cell survival and tumor growth delay post-irradiation.
• Evaluation of prenyltransferase inhibitors on human cancer cell line radiosensitivity.
• Review of clinical phase I trials using prenyltransferase inhibitors with concurrent radiotherapy.

Main Results:

• Ras activation correlates with increased clonogenic cell survival and decreased tumor growth delay following irradiation in preclinical models.
• Prenyltransferase inhibitors enhance the radiosensitivity of human cancer cell lines.
• Phase I clinical trials indicate acceptable toxicity for prenyltransferase inhibitors used with radiotherapy.

Conclusions:

• Inhibiting Ras activation is a promising molecular strategy for radiosensitization in cancer treatment.
• Prenyltransferase inhibitors represent a viable therapeutic approach to improve radiotherapy efficacy.
• Further clinical investigation of Ras pathway inhibition in combination with radiotherapy is warranted.